Vaccinia virus (ATCC® VR-1508)

Classification: Poxviridae, Orthopoxvirus  /  Strain:   Modified Vaccinia Virus Ankara (MVA)  /  Product Format: frozen 1 mL per vial

Permits and Restrictions

View Permits

Classification Poxviridae, Orthopoxvirus
Agent Vaccinia virus
Strain Modified vaccinia virus Ankara (MVA)
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Product Format frozen 1 mL per vial
Storage Conditions -70°C or colder
Comments Does not replicate in human cells or the majority of mammalian cells. This is a highly attenuated strain that some experts feel can be handled safely by trained personnel without the need for vaccination.
Effect on Host
CPE, rounding and sloughing
Recommended Host
BHK-21 (ATCC® CCL-10™)
Growth Conditions Incubation: 37°C
Recommendations for Infection: Plate cells 24-48 hours prior to infection and infect when cultures are 80-90% confluent. Remove medium and inoculate with a small volume of virus (e.g. 1 mL per 25 cm2) diluted to provide an optimal MOI (e.g. 0.1). Adsorb 1-2 hours at 37°C in a humidified 5% CO2 atmosphere, rocking every 20-30 minutes to redistribute inoculum. End adsorption by adding virus growth medium.
Incubation: 3-7 days
Effect on Host
CPE, rounding and sloughing
Name of Depositor B Moss, LS Wyatt, National Institute of Allergy and Infectious Diseases
Special Collection NCRR Contract
Chain of Custody
ATCC <-- B Moss, LS Wyatt, National Institute of Allergy and Infectious Diseases <-- A Mayr
Source CVA (Ankara) strain serially passaged in chicken embryo fibroblasts and plaque purified three times

Antoine G, et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396, 1998. PubMed: 9601507

Bernard Moss, personal communication

Mahnel H, Mayr A. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berlin Munch. Tierarztl. Wochenschr. 107: 253-256, 1994.

Meyer H, et al. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72: 1031-1038, 1991. PubMed: 2033387

Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89: 10847-10851, 1992. PubMed: 1438287

Cross References

Nucleotide (GenBank) : U94848 Vaccinia virus strain Ankara, complete genomic sequence

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation